DAFNA Capital Management LLC Buys 50,000 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

DAFNA Capital Management LLC raised its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 9.2% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 591,128 shares of the biotechnology company’s stock after purchasing an additional 50,000 shares during the period. BioCryst Pharmaceuticals comprises approximately 2.3% of DAFNA Capital Management LLC’s holdings, making the stock its 9th largest holding. DAFNA Capital Management LLC owned about 0.73% of BioCryst Pharmaceuticals worth $3,287,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Tudor Investment Corp ET AL acquired a new position in shares of BioCryst Pharmaceuticals in the 2nd quarter valued at approximately $233,000. Voya Investment Management LLC raised its position in shares of BioCryst Pharmaceuticals by 12.1% in the 2nd quarter. Voya Investment Management LLC now owns 38,275 shares of the biotechnology company’s stock valued at $213,000 after purchasing an additional 4,127 shares in the last quarter. OxFORD Asset Management LLP acquired a new position in shares of BioCryst Pharmaceuticals in the 2nd quarter valued at approximately $660,000. FMR LLC raised its position in shares of BioCryst Pharmaceuticals by 114.5% in the 2nd quarter. FMR LLC now owns 3,124,676 shares of the biotechnology company’s stock valued at $17,373,000 after purchasing an additional 1,667,791 shares in the last quarter. Finally, Vanguard Group Inc. raised its position in shares of BioCryst Pharmaceuticals by 19.9% in the 2nd quarter. Vanguard Group Inc. now owns 6,007,815 shares of the biotechnology company’s stock valued at $33,404,000 after purchasing an additional 996,052 shares in the last quarter. 70.21% of the stock is currently owned by institutional investors.

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) traded down 2.70% on Friday, hitting $5.05. The stock had a trading volume of 1,325,680 shares. The firm’s 50-day moving average price is $5.23 and its 200-day moving average price is $5.66. The firm’s market cap is $406.16 million. BioCryst Pharmaceuticals, Inc. has a 1-year low of $3.75 and a 1-year high of $9.25.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.21) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by ($0.02). BioCryst Pharmaceuticals had a negative net margin of 160.97% and a negative return on equity of 276.62%. The business had revenue of $3.10 million during the quarter, compared to the consensus estimate of $5.79 million. During the same quarter in the previous year, the firm posted ($0.22) EPS. The company’s revenue for the quarter was down 35.4% compared to the same quarter last year. On average, equities research analysts predict that BioCryst Pharmaceuticals, Inc. will post ($0.75) earnings per share for the current year.

In other BioCryst Pharmaceuticals news, Director Fred E. Cohen sold 54,250 shares of BioCryst Pharmaceuticals stock in a transaction on Monday, September 18th. The stock was sold at an average price of $5.42, for a total value of $294,035.00. Following the completion of the transaction, the director now owns 173,660 shares in the company, valued at approximately $941,237.20. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 5.80% of the company’s stock.

A number of equities analysts have issued reports on the company. Royal Bank Of Canada assumed coverage on BioCryst Pharmaceuticals in a research report on Thursday, September 14th. They issued a “sector perform” rating and a $6.00 target price on the stock. BidaskClub raised BioCryst Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Tuesday, August 1st. Piper Jaffray Companies reissued an “overweight” rating and set a $15.00 price target (up from $13.00) on shares of BioCryst Pharmaceuticals in a research report on Tuesday, September 5th. ValuEngine lowered BioCryst Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Sunday, September 3rd. Finally, J P Morgan Chase & Co upped their price target on BioCryst Pharmaceuticals from $4.93 to $9.00 and gave the company a “neutral” rating in a research report on Wednesday, September 6th. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and seven have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $8.78.

ILLEGAL ACTIVITY WARNING: “DAFNA Capital Management LLC Buys 50,000 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)” was reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this story on another website, it was stolen and republished

Several other institutional investors and hedge funds have also made changes to their positions in the business. Tudor Investment Corp ET AL acquired a new position in shares of BioCryst Pharmaceuticals in the 2nd quarter valued at approximately $233,000. Voya Investment Management LLC raised its position in shares of BioCryst Pharmaceuticals by 12.1% in the 2nd quarter. Voya Investment Management LLC now owns 38,275 shares of the biotechnology company’s stock valued at $213,000 after purchasing an additional 4,127 shares in the last quarter. OxFORD Asset Management LLP acquired a new position in shares of BioCryst Pharmaceuticals in the 2nd quarter valued at approximately $660,000. FMR LLC raised its position in shares of BioCryst Pharmaceuticals by 114.5% in the 2nd quarter. FMR LLC now owns 3,124,676 shares of the biotechnology company’s stock valued at $17,373,000 after purchasing an additional 1,667,791 shares in the last quarter. Finally, Vanguard Group Inc. raised its position in shares of BioCryst Pharmaceuticals by 19.9% in the 2nd quarter. Vanguard Group Inc. now owns 6,007,815 shares of the biotechnology company’s stock valued at $33,404,000 after purchasing an additional 996,052 shares in the last quarter. 70.21% of the stock is currently owned by institutional investors.

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) traded down 2.70% on Friday, hitting $5.05. The stock had a trading volume of 1,325,680 shares. The firm’s 50-day moving average price is $5.23 and its 200-day moving average price is $5.66. The firm’s market cap is $406.16 million. BioCryst Pharmaceuticals, Inc. has a 1-year low of $3.75 and a 1-year high of $9.25.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.21) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by ($0.02). BioCryst Pharmaceuticals had a negative net margin of 160.97% and a negative return on equity of 276.62%. The business had revenue of $3.10 million during the quarter, compared to the consensus estimate of $5.79 million. During the same quarter in the previous year, the firm posted ($0.22) EPS. The company’s revenue for the quarter was down 35.4% compared to the same quarter last year. On average, equities research analysts predict that BioCryst Pharmaceuticals, Inc. will post ($0.75) earnings per share for the current year.

In other BioCryst Pharmaceuticals news, Director Fred E. Cohen sold 54,250 shares of BioCryst Pharmaceuticals stock in a transaction on Monday, September 18th. The stock was sold at an average price of $5.42, for a total value of $294,035.00. Following the completion of the transaction, the director now owns 173,660 shares in the company, valued at approximately $941,237.20. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 5.80% of the company’s stock.

A number of equities analysts have issued reports on the company. Royal Bank Of Canada assumed coverage on BioCryst Pharmaceuticals in a research report on Thursday, September 14th. They issued a “sector perform” rating and a $6.00 target price on the stock. BidaskClub raised BioCryst Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Tuesday, August 1st. Piper Jaffray Companies reissued an “overweight” rating and set a $15.00 price target (up from $13.00) on shares of BioCryst Pharmaceuticals in a research report on Tuesday, September 5th. ValuEngine lowered BioCryst Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Sunday, September 3rd. Finally, J P Morgan Chase & Co upped their price target on BioCryst Pharmaceuticals from $4.93 to $9.00 and gave the company a “neutral” rating in a research report on Wednesday, September 6th. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and seven have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $8.78.

ILLEGAL ACTIVITY WARNING: “DAFNA Capital Management LLC Buys 50,000 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)” was reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this story on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this story can be read at https://ledgergazette.com/2017/10/14/dafna-capital-management-llc-has-3-29-million-holdings-in-biocryst-pharmaceuticals-inc-bcrx.html.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.

Institutional Ownership by Quarter for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Ratings for BioCryst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply